Study Title

Phase 1 Imaging Study of 68Ga-R10602-101 in Hormone Receptor-Positive Breast Cancer

Study Details

Description:

A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.

Sponsor:

Radionetics Oncology

Contacts:

Yael Cohen-Arazi

r10602-101@radionetics.com

858-373-7793

Kristrun Stardal

r10602-101@radionetics.com

949-887-9494

Drug Details

68Ga-R10602
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • G protein-coupled receptors (GPCRs)

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468